In contrast, taspoglutides development was halted due to severe immunogenic and hypersensitivity complications
Vanda CEO Mihael Polymeropoulos called the drug a familiar therapeutic agent that offers flexible dosing with a well-known safety profile. April 1 Product: AstraZenecas Voydeya Indication: Paroxysmal nocturnal haemoglobinuria AstraZeneca kicked off April with a win for its rare disease portfolio as the FDA approved Voydeya, an oral, first-in-class factor D inhibitor to treat a subset of patients with paroxysmal nocturnal haemoglobinuria (PNH)
As evidence evolves, many providers are reconsidering which therapies deliver both glycemic control and cardiovascular Read More GLP-1 Resistance in Clinical Practice: What New Genetic Insights May Explain Apr 20, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 4,759 views Why do some patients respond dramatically to GLP-1 therapies while others see little benefit
By lowering inflammation in the brain, semaglutide could improve overall brain health, which may, in turn, lessen OCD symptoms
